Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (CSTL) delivers innovative diagnostic solutions that transform cancer care through genomic insights. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in precision oncology diagnostics.
Access authoritative information about CSTL’s latest developments, including new test validations, clinical study results, and strategic partnerships. Our curated collection features earnings reports, regulatory milestones, and research breakthroughs across key focus areas like melanoma diagnostics and pharmacogenomics.
Stay informed about critical updates including:
- FDA-cleared test announcements
- Peer-reviewed study publications
- Financial performance reports
- Collaborative oncology initiatives
- Expanded clinical utility data
Bookmark this page for streamlined access to Castle Biosciences’ verified news. Check regularly for updates that impact diagnostic practices and investment considerations in the genomic testing sector.
Castle Biosciences (Nasdaq: CSTL) announced a partnership with the Melanoma Research Foundation to present the 'Ask the Expert' Managing Melanoma webinar series during April 2021. This initiative aims to enhance awareness and education regarding melanoma, featuring expert discussions on topics such as tumor genetics and gene expression profiling. The webinars will be broadcast live on the MRF Facebook page, providing vital resources for patients and promoting early detection and prevention of melanoma.
Castle Biosciences (Nasdaq: CSTL) has announced that CEO Derek Maetzold will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 4:30 p.m. ET. The presentation will focus on the company's innovative genomic tests aimed at improving cancer treatment decisions for patients with skin cancers. A live audio webcast will be accessible via Castle Biosciences' website, with a replay available for two weeks post-event.
Castle specializes in personalized genomic information for various dermatologic cancers, enhancing decision-making for physicians and patients.
Castle Biosciences (Nasdaq: CSTL) announced a study showing increasing use of its DecisionDx®-Melanoma test among dermatologists for managing melanoma patients. The study featured responses from 589 U.S. dermatologists, revealing that 45% ordered the test in the last year, with 82% likely to do so moving forward. DecisionDx-Melanoma significantly influences treatment decisions, particularly for early-stage melanomas, with a Class 1A result showing a 96.8% 5-year recurrence-free survival rate. Dermatologists reported benefits for patients, such as reduced anxiety and improved treatment personalization.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced its financial results for 2020, achieving revenues of $62.6 million, up 21% from 2019. The company expanded its product offerings to three skin cancer tests, increasing its U.S. total addressable market to $2 billion. The integrated AI-based DecisionDx-Melanoma test was launched, promising improved risk predictions. However, operating cash flow dropped to $9.9 million, and fourth-quarter revenue slightly declined to $17.3 million. With $410 million in cash, the company remains positioned for growth, predicting an additional $3.6 billion market opportunity.
Castle Biosciences (Nasdaq: CSTL) announced enhancements to its DecisionDx®-Melanoma test, now featuring an Integrated Test Result (ITR) that provides improved risk predictions for melanoma patients. This update is driven by an AI-based algorithm (i31-GEP) validated through testing of 1,674 patients. The updated test not only predicts sentinel lymph node positivity but also offers 5-year survival outcomes. An app for dermatology clinicians will be launched later in 2021, utilizing the ITR to enhance patient management decisions. DecisionDx-Melanoma has been ordered over 68,920 times to date.
Castle Biosciences, Inc. (Nasdaq: CSTL) will announce its fourth-quarter and full-year financial results for 2020 after the market closes on March 8, 2021. A conference call and webcast will follow at 4:30 p.m. Eastern time to discuss these results and a corporate update. Interested parties can access the live webcast through the company’s Investor Relations page or by phone. Castle Biosciences focuses on providing personalized genomic information for skin cancer treatment decisions, offering tests for various melanoma types and other dermatologic diseases.
Castle Biosciences (Nasdaq: CSTL) announced that CEO Derek Maetzold will present at two investor conferences. The first is the BTIG Virtual MedTech Conference on Feb. 17, 2021, at 10:30 a.m. ET, followed by the 10th Annual SVB Leerink Global Healthcare Conference on Feb. 24, 2021, at 10:00 a.m. ET. Live webcasts of the presentations will be available on Castle's website, with replays accessible for two weeks afterward. Castle focuses on providing personalized genomic information to enhance treatment decisions for skin cancer.
Castle Biosciences (Nasdaq: CSTL) announced the presentation of virtual posters at the 19th Annual South Beach Symposium, highlighting its gene expression profile tests for skin cancer. Key studies include DecisionDx-Melanoma, which predicts melanoma metastasis risk, revealing that 75% of patients with T1b tumors could avoid sentinel lymph node biopsy, potentially saving $120 million in healthcare costs. DecisionDx DiffDx-Melanoma showed high diagnostic accuracy (99.1% sensitivity) and improved clinician confidence. DecisionDx-SCC aids in predicting metastasis risk in high-risk cutaneous SCC patients, improving management decisions.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced poster presentations featuring data on its skin cancer gene expression profile tests at the 18th Annual Winter Clinical Dermatology Conference from Jan. 15 – 24, 2021. The tests include DecisionDx®-Melanoma, which predicts melanoma metastasis risk, and DecisionDx® DiffDx™-Melanoma, designed for classifying difficult lesions. Key findings reveal DecisionDx-Melanoma significantly predicts sentinel lymph node positivity, while DecisionDx DiffDx-Melanoma boasts 98% sensitivity and 100% specificity in head and neck lesions.
Castle Biosciences (Nasdaq: CSTL) released preliminary performance results for Q4 and full-year 2020. Despite COVID-19 challenges, the company reported growth in DecisionDx®-Melanoma test reports, delivering 4,246 in Q4 and 16,232 for the year. They expanded their skin cancer product suite and launched the DecisionDx DiffDx-Melanoma test. The total addressable market for its tests is now estimated at $2 billion. Key financial highlights include a public offering that raised $266.8 million, boosting cash reserves to approximately $410 million by year-end.